Compound News and Research

RSS

New research suggests that humans can perceive certain scents as threatening

New research from a team led by a psychologist at the University of Kent suggests that humans, like other species, can perceive certain scents as threatening.

20 Oct 2015

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Takeda Pharmaceuticals, U.S.A., Inc., today announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2015 American College of Gastroenterology Annual Scientific Meeting in Honolulu, Hawaii, held on October 16-21.

20 Oct 2015

Nanodiamonds may improve outcomes for patients undergoing root canals

People undergoing root canals may have gained a powerful, if tiny, new ally. Researchers from the UCLA School of Dentistry have found that using nanodiamonds to fortify a material used in the procedure could significantly improve outcomes for patients.

19 Oct 2015

TGen researchers join international scientists in discovering how malaria protein could some day help stop cancer

Researchers at the Translational Genomics Research Institute joined an international team of scientists in discovering how a protein from malaria could some day help stop cancer.

19 Oct 2015

FDA grants accelerated approval to Praxbind (idarucizumab)

The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa's blood-thinning effects.

19 Oct 2015

BET protein family plays key role in regulation of normal neuronal development and function

Regulation of a family of brain proteins known as bromodomain and extra-terminal domain containing transcription regulators (BETs) plays a key role in normal cognition and behavior, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published advanced online on September 21 and in print October 19 in The Journal of Experimental Medicine.

19 Oct 2015

Malaria protein could one day help stop cancer

Scientists at the University of British Columbia, Vancouver Coastal Health and the BC Cancer Agency have discovered a protein from malaria that could one day help stop cancer in its tracks.

13 Oct 2015

RE.WORK showcases future technology and innovations in deep learning software

The future of technological innovation is a broad topic with endless opportunities in every scientific field. RE.WORK’s two most recent concurrent conferences ‘RE.WORK: Future Technology’ and ‘RE.WORK: Deep Learning’, in part focussed on putting healthcare in the context of the wider technological revolution.

13 Oct 2015

Researchers explore how nitrate-rich beet juice may affect high altitude acclimatization

Ever since human beings first began climbing the world's tallest mountains, they have struggled with a basic problem: altitude sickness, caused by lower air pressures which affect the ability of our bodies to take up oxygen.

12 Oct 2015

Antiviral agent protects rhesus monkeys from deadly Ebola virus

Rhesus monkeys were completely protected from the deadly Ebola virus when treated three days after infection with a compound that blocks the virus's ability to replicate. These encouraging preclinical results suggest the compound, known as GS-5734, should be further developed as a potential treatment, according to research findings to be presented tomorrow at the IDWeek conference.

12 Oct 2015

YK-4-279 compound works against some forms of leukemia: Study

A compound discovered and developed by a team of Georgetown Lombardi Comprehensive Cancer Center researchers that halts cancer in animals with Ewing sarcoma and prostate cancer appears to work against some forms of leukemia, too.

12 Oct 2015

Research finding offers hope for more powerful aspirin-like drugs

Researchers have found that salicylic acid targets the activities of HMGB1, an inflammatory protein associated with a wide variety of diseases, offering hope that more powerful aspirin-like drugs may be developed.

11 Oct 2015

Brain & Behavior Research Foundation to honor nine scientists with Outstanding Achievement Prizes

The Brain & Behavior Research Foundation will honor nine scientists with its 2015 Outstanding Achievement Prizes for their work in schizophrenia, mood disorders, child and adolescent psychiatry, and cognitive neuroscience.

9 Oct 2015

Celtaxsys commences acebilustat phase 2 trial in patients with cystic fibrosis in US

Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today the commencement of the US arm of an international phase 2 clinical trial for its flagship compound, acebilustat, in patients with cystic fibrosis (CF).

8 Oct 2015

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim's investigational biologic compound BI 655066, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab.

8 Oct 2015

New studies suggest ways to improve cancer care by inhibiting oncogenes, boosting tumor-suppressor activity

Two new studies by cancer scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggest new approaches for treating cancer by inhibiting overactive cancer-promoting genes and by enhancing the activity of sluggish tumor-suppressor genes.

7 Oct 2015

OLFUS study supports safety, efficacy of DBV's Viaskin Peanut patch in children with peanut allergy

DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term safety and efficacy of Viaskin Peanut for the treatment of peanut allergy.

7 Oct 2015

New flame retardant created to replace commercial additives that are often toxic

Inspired by a naturally occurring material found in marine mussels, researchers at The University of Texas at Austin have created a new flame retardant to replace commercial additives that are often toxic and can accumulate over time in the environment and living animals, including humans.

6 Oct 2015

Living 'green' walls may affect health of office workers

New research by University of York academics reveals that living 'green' walls may have adverse health effects on office workers living in hot, polluted climates.

5 Oct 2015

Neuroendocrine sequelae common after paediatric optic gliomas

Neuroendocrine sequelae are common following paediatric low-grade gliomas affecting the optic pathway, hypothalamus and suprasellar areas and are influenced by tumour location and treatment choice, a study shows.

1 Oct 2015

Compound News and Research

New research suggests that humans can perceive certain scents as threatening

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Nanodiamonds may improve outcomes for patients undergoing root canals

TGen researchers join international scientists in discovering how malaria protein could some day help stop cancer

FDA grants accelerated approval to Praxbind (idarucizumab)

BET protein family plays key role in regulation of normal neuronal development and function

Malaria protein could one day help stop cancer

RE.WORK showcases future technology and innovations in deep learning software

Researchers explore how nitrate-rich beet juice may affect high altitude acclimatization

Antiviral agent protects rhesus monkeys from deadly Ebola virus

YK-4-279 compound works against some forms of leukemia: Study

Research finding offers hope for more powerful aspirin-like drugs

Brain & Behavior Research Foundation to honor nine scientists with Outstanding Achievement Prizes

Celtaxsys commences acebilustat phase 2 trial in patients with cystic fibrosis in US

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

New studies suggest ways to improve cancer care by inhibiting oncogenes, boosting tumor-suppressor activity

OLFUS study supports safety, efficacy of DBV's Viaskin Peanut patch in children with peanut allergy

New flame retardant created to replace commercial additives that are often toxic

Living 'green' walls may affect health of office workers

Neuroendocrine sequelae common after paediatric optic gliomas

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News